Tag Archives: Regeneron

Morgan Stanley Maintains a Hold Rating on Regeneron (REGN)

In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on Regeneron (REGN – Research Report), with a price target of $611.00. The company’s shares closed last Thursday at $615.57, close to its 52-week high of

Analysts Conflicted on These Healthcare Names: Regeneron (NASDAQ: REGN), Nevro Crop (NYSE: NVRO) and Horizon Therapeutics (NASDAQ: HZNP)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Regeneron (REGN – Research Report), Nevro Crop (NVRO – Research Report) and Horizon Therapeutics (HZNP – Research Report). Regeneron (REGN) Citigroup analyst Mohit Bansal maintained

Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN) and Avrobio (NASDAQ: AVRO)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Regeneron (REGN – Research Report) and Avrobio (AVRO – Research Report). Regeneron (REGN) Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Regeneron today

Oppenheimer Believes Regeneron (NASDAQ: REGN) Won’t Stop Here

In a report released today, Hartaj Singh from Oppenheimer assigned a Buy rating to Regeneron (REGN – Research Report), with a price target of $625.00. The company’s shares closed last Monday at $599.47, close to its 52-week high of $615.36.

Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN), Incyte (NASDAQ: INCY) and Inogen (NASDAQ: INGN)

Analysts fell to the sidelines weighing in on Regeneron (REGN – Research Report), Incyte (INCY – Research Report) and Inogen (INGN – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Regeneron

Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN) and Premier (NASDAQ: PINC)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Regeneron (REGN – Research Report) and Premier (PINC – Research Report). Regeneron (REGN) In a report released yesterday, Evan Seigerman from Credit Suisse reiterated a